Promising Potential of Nalfurafine in Opioid Pain Treatment

Diversity of Pain and Treatment Options

Pain is a multifaceted experience, manifesting in various forms. For instance, the sensation of pain from a sunburn differs significantly from that of a headache. Similarly, the treatments available for pain management are diverse, with different pain relievers targeting specific pathways in the nervous system to alleviate discomfort. While opioids, such as morphine, are among the most recognized and effective pain relievers, their use is accompanied by considerable side effects including constipation, nausea, and the risk of addiction.

Renewed Interest in Opioid Alternatives

The escalating opioid addiction crisis has sparked renewed interest in identifying opioid-sparing pain relievers or alternatives. A recent study published in *The Journal of Pharmacology and Experimental Therapeutics* explores the potential of nalfurafine, an anti-itch medication, as an adjunct in pain management and as a strategy to combat opioid over-prescription.

Study Design and Findings

Researchers from the United States conducted experiments using mouse models to compare the efficacy of morphine alone against morphine combined with nalfurafine. The study administered a variety of doses to determine the minimum effective dose for pain relief. Results indicated that a small dose of nalfurafine combined with a lower dose of morphine provided equivalent pain relief to a higher dose of morphine alone. This finding suggests that patients could potentially achieve effective pain management with reduced doses of both medications, thereby minimizing the risk of addiction and substance abuse.

Pharmacological Differences of Nalfurafine

Although nalfurafine is classified as an opioid, it operates differently within the body compared to morphine. Morphine primarily targets mu opioid receptors, which alleviate pain but also activate reward pathways that can lead to addiction. In contrast, nalfurafine interacts with kappa opioid receptors, reducing pain without triggering the same reward feedback mechanisms. Furthermore, early clinical studies indicate that nalfurafine does not produce the severe dysphoria associated with other kappa opioid receptor agonists.

Implications for Pain Management

The findings suggest that nalfurafine could serve as a beneficial adjunct to opioid medications for pain relief. By supplementing nalfurafine, it may be possible to lower the required doses of addictive opioids, thereby mitigating the risks associated with opioid use. Prevention is crucial in addressing the opioid addiction crisis, and nalfurafine could play a significant role in this effort.

References

Kaski, S. W., White, A. N., Gross, J. D., Trexler, K. R., Wix, K., Harland, A. A., … Setola, V. (2019). Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine. *Journal of Pharmacology and Experimental Therapeutics*, 371(2), 487–499. doi: 10.1124/jpet.118.255661

Fighting opioids with an unlikely supplemental painkiller: Anti-itch medicine. (2019, November 21). Retrieved from https://www.eurekalert.org/pub_releases/2019-11/wvu-fow112119.php

Image by Arek Socha from Pixabay